Swami Murugappan is an experienced drug development leader serving as the Consulting Chief Medical Officer at Triumvira Immunologics. He is the founder and owner of Trident Bio Consulting Inc., which helps drive strategy and execution for life sciences organizations developing therapeutics for life-threatening illnesses. Previously, he was the Vice President at Nutcracker Therapeutics, a mRNA platform company, where he led non-clinical, clinical, and regulatory functions and was responsible for taking programs from research to IND. Before Nutcracker, Swami was the Executive Director and global product lead for a CD19 CAR-T (Tecartus™) at Kite Pharma, where he led a successful US and EU filing and subsequent FDA approval of Tecartus™ for relapsed and refractory mantle cell lymphoma. Before Kite, Swami worked at Amgen in early and late-phase oncology programs within clinical development and supported global filings and approvals of Vectibix™ and ImLygic™ (first-in-class Oncolytic virus).
Swami is an ABIM board-certified Hematologist and Oncologist. He completed his fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center after his Internal Medicine training at Drexel University. He graduated from Temple University with his Ph.D. in Physiology and received his MD from Chennai Medical College, India.
